Asgard Therapeutics has appointed Prof Dr Wolfram Brugger as Chief Medical Officer, strengthening its leadership team as the company prepares to transition into a clinical-stage biotech.
Wolfram has participated in more than 130 phase 1–3 oncology trials across multiple cancer types and modalities, including solid tumours.
Announcing the appointment, Cristiana Pires, Co-founder and Chief Executive Officer of Asgard Therapeutics, said: “Strengthening our leadership team with Wolfram, who is such a highly experienced clinical trials expert and practising medical oncologist, is a privilege and we are excited to welcome him on board.”
Wolfram said: “I’ve always been driven by bringing new modalities to patients, and I am excited to be developing a ‘personalised off-the-shelf’ immunotherapy which has great potential to help patients with a wide variety of cancers.
“Asgard’s in vivo cell reprogramming technology has transformative potential, and the preclinical proof-of-concept data, both published and upcoming data to be presented at key scientific conferences, is highly convincing.”
Wolfram joins from Autolus Therapeutics, where he led the global clinical development of AUTO1, an autologous CD19 CAR-T therapy approved by the FDA in 2024 for relapsed or refractory B-cell acute lymphoblastic leukaemia and granted conditional approval by the EMA and MHRA in 2025.
His previous roles include leading global clinical development programmes at MorphoSys and serving as global medical lead at AstraZeneca for phase 1 and early phase 2 oncology trials.
